Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $69.18

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $69.18.

A number of equities analysts have issued reports on the stock. Guggenheim cut shares of Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Immunocore in a research report on Monday, September 9th. Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $72.00 to $38.00 in a report on Monday, November 11th. UBS Group assumed coverage on Immunocore in a research note on Thursday, October 24th. They issued a "sell" rating and a $24.00 price target on the stock. Finally, Needham & Company LLC reduced their price target on Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a research note on Thursday, November 7th.

Immunocore Stock Down 3.4 %

Shares of IMCR traded down $1.08 during mid-day trading on Wednesday, reaching $30.77. The company's stock had a trading volume of 248,727 shares, compared to its average volume of 498,550. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -33.53 and a beta of 0.73. The business has a fifty day moving average of $32.33 and a 200 day moving average of $35.55. Immunocore has a 1 year low of $29.72 and a 1 year high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million during the quarter, compared to analysts' expectations of $78.94 million. During the same quarter in the previous year, the firm earned ($0.59) EPS. The firm's revenue was up 23.7% compared to the same quarter last year. As a group, analysts forecast that Immunocore will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMCR. Pier Capital LLC raised its stake in Immunocore by 1.4% during the third quarter. Pier Capital LLC now owns 82,480 shares of the company's stock worth $2,568,000 after buying an additional 1,174 shares during the last quarter. XTX Topco Ltd raised its holdings in Immunocore by 72.9% during the third quarter. XTX Topco Ltd now owns 15,459 shares of the company's stock worth $481,000 after buying an additional 6,516 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company's stock valued at $219,430,000 after purchasing an additional 668,382 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in Immunocore by 65.6% during the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock worth $23,587,000 after acquiring an additional 300,200 shares during the last quarter. Finally, State Street Corp lifted its holdings in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company's stock worth $2,387,000 after acquiring an additional 29,897 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.